NCT05902520View on ClinicalTrials.gov

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 19, 2023

Primary Completion Date

May 19, 2025

Study Completion Date

May 19, 2026

Conditions
HNSCCMelanomaGynecologic CancerColorectal CancerLung CancerUrogenital Cancer
Interventions
BIOLOGICAL

DP CD8 TIL

intravenous infusion of T cell suspension

BIOLOGICAL

DP CD8 TIL KD

intravenous infusion of T cell suspension

BIOLOGICAL

Low dose IL-2

Low dose IL-2 delivered subcutaneously for 1, 2 or 3 weeks

Trial Locations (1)

97213

RECRUITING

Providence Portland Medical Center, Portland

Sponsors

Collaborators (1)

Phio Pharmaceuticals Inc.
All Listed Sponsors
collaborator

Phio Pharmaceuticals Inc.

INDUSTRY

collaborator

Providence St Joseph Health

UNKNOWN

lead

AgonOx, Inc.

INDUSTRY